Anna Turetsky joined The Mark Foundation as Principal, Venture Investments in November 2019. As the head of the foundation’s venture arm, she has led its investments in and serves as a board observer for Accent Therapeutics, C2i Genomics (acquired by Veracyte), Hyku Biosciences, Immunitas Therapeutics, Interius Biotherapeutics, and Vicinitas Therapeutics. She is also a Board Director at Verseau Therapeutics. Prior to this, Anna was a Vice President at Lightstone Ventures, a global, early-stage venture fund investing in the biopharmaceutical and medical device sectors. She played a major role in the firm’s investments in Tizona Therapeutics (acquired by Gilead), Gemini Therapeutics (NASDAQ: GMTX), Cyteir Therapeutics (NASDAQ: CYT), Disarm Therapeutics (acquired by Eli Lilly), and Locanabio, and served as an observer on the boards of these companies. Anna’s additional work experience includes internships and strategic consulting for corporate venture funds and biotech companies. Anna holds a PhD in Biophysics from Harvard University, where she was an NSF Graduate Research Fellow, and a BA in Biochemistry from the University of Pennsylvania, where she was a Vagelos Science Scholar.